

PCT7GB 03/039// A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K39/00 A61K Ä6ĪK39/39 A61P35/00 C12N15/12 C07K14/47 C12N5/06 C12N15/63 C12N15/863 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) BIOSIS, EPO-Internal, EMBASE, WPI Data, PAJ, MEDLINE C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category ° "IMMUNOPOTENTIATION WITH 1 - 14BASS K K ET AL: X LOW-DOSE CYCLOPHOSPHAMIDE IN THE ACTIVE SPECIFIC IMMUNOTHERAPY OF CANCER" 16-19 CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 47, 1998, pages 1-12, XP002924273 ISSN: 0340-7004 page 2, right-hand column, paragraph 1 paragraph 2 page 3, left-hand column, paragraph 3 page 3, right-hand column, paragraph 2 page 3, right-hand column, paragraph 4 page 5, right-hand column, paragraph 4 Patent family members are listed in annex. Further documents are listed in the continuation of box C. Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the *A* document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the International "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled "O" document referring to an oral disclosure, use, exhibition or in the art. document published prior to the international filing date but later than the priority date claimed *&" document member of the same patent family Date of mailing of the International search report Date of the actual completion of the international search 26/02/2004 10 February 2004 Name and mailing address of the ISA Authorized officer

European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016

Irion, A



PCT7GB 03/03977

BAARS A ET AL: "A phase II study of active specific immunotherapy and	1-4,9-19
active specific immunotherapy and	1-4,9-19
5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma" BRITISH JOURNAL OF CANCER, vol. 86, no. 8, 22 April 2002 (2002-04-22), pages 1230-1234, XP002269716 ISSN: 0007-0920 page 1231, right-hand column, paragraph 2 paragraph 3	
URUSHIZAKI I: "Recent view of tumor dormancy therapy" BIOTHERAPY 2003 JAPAN, vol. 17, no. 4, 2003, pages 331-338, XP009025509 ISSN: 0914-2223 abstract	1-19
WO 03 097092 A (HIMMLER GOTTFRIED ;LOIBNER HANS (AT); IGENEON KREBS IMMUNTHERAPIE) 27 November 2003 (2003-11-27) page 12, paragraph 5 -page 13, paragraph 1 page 18, paragraph 3 page 19, paragraph 3	1–19
WO 01 56601 A (BERD DAVID ;UNIV JEFFERSON (US)) 9 August 2001 (2001-08-09) the whole document	1–19
KLEMENT GIANNOULA ET AL: "Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity" JOURNAL OF CLINICAL INVESTIGATION, vol. 105, no. 8, April 2000 (2000-04), pages R15-R24, XP002269717 ISSN: 0021-9738 cited in the application the whole document	1–19
HANAHAN DOUGLAS ET AL: "Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice" JOURNAL OF CLINICAL INVESTIGATION, vol. 105, no. 8, April 2000 (2000-04), pages 1045-1047, XP002269718 ISSN: 0021-9738 the whole document -/	1-19
	22 April 2002 (2002-04-22), pages 1230-1234, XP002269716 ISSN: 0007-0920 page 1231, right-hand column, paragraph 2 - paragraph 3 URUSHIZAKI I: "Recent view of tumor dormancy therapy" BIOTHERAPY 2003 JAPAN, vol. 17, no. 4, 2003, pages 331-338, XP009025509 ISSN: 0914-2223 abstract WO 03 097092 A (HIMMLER GOTTFRIED ;LOIBNER HANS (AT); IGENEON KREBS IMMUNTHERAPIE) 27 November 2003 (2003-11-27) page 12, paragraph 5 -page 13, paragraph 1 page 18, paragraph 3 page 19, paragraph 3 page 19, paragraph 3 WO 01 56601 A (BERD DAVID ;UNIV JEFFERSON (US)) 9 August 2001 (2001-08-09) the whole document KLEMENT GIANNOULA ET AL: "Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity" JOURNAL OF CLINICAL INVESTIGATION, vol. 105, no. 8, April 2000 (2000-04), pages R15-R24, XP002269717 ISSN: 0021-9738 cited in the application the whole document HANAHAN DOUGLAS ET AL: "Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice" JOURNAL OF CLINICAL INVESTIGATION, vol. 105, no. 8, April 2000 (2000-04), pages 1045-1047, XP002269718 ISSN: 0021-9738 the whole document





C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Α BROWDER T ET AL: "ANTIANGIOGENIC 1-19 SCHEDULING OF CHEMOTHERAPY IMPROVES EFFICACY AGAINSTEXPERIMENTAL DRUG-RESISTANT CANCER" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 7, 1 April 2000 (2000-04-01), pages 1878-1886, XP001026181 ISSN: 0008-5472 cited in the application the whole document MAN SHAN ET AL: Α "Antitumor effects in 1-19 mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water" CANCER RESEARCH. vol. 62, no. 10, 15 May 2002 (2002-05-15), pages 2731-2735, XP002269719 ISSN: 0008-5472 the whole document Α HOON D S B ET AL: "SUPPRESSOR CELL 1-19 ACTIVITY IN A RANDOMIZED TRIAL OF PATIENTS RECEIVING ACTIVE SPECIFIC IMMUNOTHERAPY WITH MELANOMA CELL VACCINE AND LOW DOSAGES OF CYCLOPHOSPHAMIDE" CANCER RESEARCH, vol. 50, no. 17, 1990, pages 5358-5364, XP001179425 ISSN: 0008-5472 the whole document T HERMANS IAN F ET AL: "Synergistic effect 1-19 of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model." CANCER RESEARCH. vol. 63, no. 23, 1 December 2003 (2003-12-01), pages 8408-8413, XP002269720 ISSN: 0008-5472 (ISSN print) the whole document

INTERNATIONAL SEARCH REPORT

PCT/GB 03/03977

Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 18 and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This int	ernational Searching Authority found multiple inventions in this international application, as follows:
ļ	
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4	No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remar	the additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.



Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03097092	Α	27-11-2003	WO	03097092 A1	27-11-2003
WO 0156601	Α	09-08-2001	AU CA EP WO US	3325701 A 2399603 A1 1253940 A2 0156601 A2 2002009469 A1	14-08-2001 09-08-2001 06-11-2002 09-08-2001 24-01-2002